Real-World Outcomes of Neoadjuvant Dual Blockade in HER2-Positive Breast Cancer: The Role of Tumor Biology and pCR.

J Clin Med · 2026 · PMC13026146 · PMID 41899145

Europe PMC DOI

hedged sentences

0.0540

closest p · 1.1× alpha

0.2570

boldest claim

The sentences

a strong trendp = 0.054so close (0.05 < p ≤ 0.1)

The non-anthracycline TCHP regimen showed a strong trend toward superior efficacy (OR = 2.22; p = 0.054). pCR was the sole independent predictor of OS (HR = 0.134; p = 0.009).

also in 5,725 other papers

borderline significantp = 0.056so close (0.05 < p ≤ 0.1)

Additionally, hormone receptor negativity showed a strong trend toward poor prognosis, with a 2.54-fold increased risk of death (HR = 2.539), although this association was borderline significant ( p = 0.056; 95% CI: 0.977–6.604) ( Table 2 ).

also in 11,409 other papers

did not reach statistical significancep = 0.257not close (p > 0.1)

Similarly, although the non-anthracycline (TCHP) arm exhibited an excellent profile with no recurrence events during follow-up (100% DFS), the difference compared to the anthracycline-based arm did not reach statistical significance ( p = 0.257).

also in 111,027 other papers

highly significantno p-value reported

Similarly, a highly significant association was observed between hormone receptor status and treatment outcome; the pCR rate was substantially higher in hormone-negative patients compared to hormone-positive patients (68.8% vs. 42.8%; p < 0.001), and hormone negativity emerged as a strong predictor associated with a 2.94-fold increase in the odds of achieving pCR (OR = 2.942; 95% CI: 1.755–4.933; p < 0.001).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.